Table 2.
Experimental design of the 5-choice serial reaction time task (5-CSRTT) study
| Week of testing | 5-CSRTT variant | Treatment | Dose mg/kg (N) | Treatment | Dose mg/kg (N) | ||
|---|---|---|---|---|---|---|---|
| 1 | I | SD = 1 s | (R)-Ketamine |
veh (12) 7.5 (13) 15 (13) |
(S)-Ketamine |
veh (13) 3.75 (13) 7.5 (12) |
|
| 2 | I | SD = 1 s | |||||
| 5 | II | SD = 2 s |
veh (12) 7.5 (13) 15 (13) |
veh (12) 3.75 (13) 7.5 (13) |
|||
| 6 | II | SD = 2 s | |||||
| 7 | III | Variable ITI |
veh (13) 7.5 (13) 15 (13) |
veh (12) 3.75 (13) 7.5 (13) |
|||
| 8 | III | Variable ITI | |||||
| 9 | I | SD = 1 s | Psilocybin | veh (13); 0.3 (13); 1 (8) | |||
| 11 | I | SD = 1 s | Psilocin | veh (14); 0.22 (13); 0.72 (8) | |||
| 14 | I | SD = 1 s | Norpsilocin | veh (12); 0.22 (13); 0.72 (13) | |||
| 16 | I | SD = 1 s | (R)-Ketamine |
veh (12) 30 (15) |
(S)-Ketamine |
veh (13) 15 (14) |
|
| 17 | I | SD = 1 s | |||||
| 18 | II | SD = 2 s |
veh (13) 30 (15) |
veh (13) 15 (15) |
|||
| 18 | II | SD = 2 s | |||||
| 20 | III | Variable ITI |
veh (19) 30 (20) |
veh (17) 15 (20) |
|||
| 21 | III | Variable ITI | |||||
| 22 | II | SD = 2 s | Psilocybin | veh (12); 0.3 (13); 1 (8) | |||
| 22 | II | SD = 2 s | Psilocin | veh (11); 0.22 (13); 0.72 (10) | |||